Performance & Vitality · Reviewed by Ian K. Tseng, MD
What Is NAD+? The Coenzyme That Is Not a Peptide
NAD+ appears on nearly every peptide menu, including ours, and it is not a peptide at all. It is a coenzyme — a different class of molecule entirely — and the reason it keeps company with peptides is practical rather than biochemical. Since the distinction affects how you should evaluate claims about it, it is worth starting there.
Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director
The short answer
NAD+ — nicotinamide adenine dinucleotide — is a coenzyme present in every living cell, not a peptide. It is central to the redox reactions that produce cellular energy and serves as a required substrate for enzyme families including the sirtuins and PARPs. Cellular NAD+ levels decline with age. It is administered intravenously, by subcutaneous injection, and through oral precursor compounds, and these routes differ meaningfully in bioavailability.
Coenzyme, not peptide
Peptides are chains of amino acids. NAD+ is a dinucleotide — a molecule built from two nucleotides joined through phosphate groups, one containing adenine and the other nicotinamide, which is derived from vitamin B3. Structurally it has nothing in common with a peptide.
It appears alongside peptides on wellness menus because it occupies a similar clinical position: an injectable compound aimed at cellular energy and healthy aging, prescribed and administered in similar settings. The grouping is operational, not biochemical. We flag it because "is this a peptide" is a reasonable question and the honest answer is no.
What NAD+ actually does
NAD+ has two broad roles. The first is as an electron carrier in redox reactions. In cellular respiration, NAD+ accepts electrons to become NADH, carries them to the mitochondrial electron transport chain, and releases them to drive ATP production. Essentially every cell depends on this cycle continuously; without adequate NAD+, energy production itself is constrained.
The second role is as a consumed substrate. Certain enzyme families do not merely use NAD+ catalytically but cleave it, consuming it in the process. The sirtuins — implicated in metabolic regulation and studied extensively in aging research — are NAD+-dependent. So are the PARP enzymes involved in DNA repair. Because these enzymes consume NAD+ rather than recycling it, sustained demand on them draws down the available pool.
What NAD+ does in a cell
A second, separate role: the sirtuins and PARP enzymes do not recycle NAD+ — they consume it. Sustained demand on those enzymes draws down the available pool.
The age-related decline
Tissue NAD+ levels decline with age across multiple studied tissues. The mechanisms proposed involve both reduced synthesis and increased consumption — notably by PARP enzymes responding to accumulated DNA damage, and by other NAD+-consuming enzymes whose activity increases with age.
This decline is the basis of research interest in restoring NAD+ levels. It is important to be careful about the inferential step, though: that a molecule declines with age and is required for processes that also decline does not by itself establish that supplementing it reverses those processes. Research examining that question in humans is ongoing and remains an active area rather than a settled one.
Delivery routes and why they differ
NAD+ is administered several ways, and the differences are not trivial. Intravenous administration delivers it directly to the bloodstream, bypassing digestive breakdown; infusions are typically slow, because rapid administration is associated with uncomfortable effects including chest tightness and nausea. We offer this route as part of our IV therapy menu.
Subcutaneous injection is used for smaller, more frequent dosing without an infusion appointment. Nasal and oral routes exist as well, and oral supplementation more commonly uses precursor molecules — nicotinamide riboside and nicotinamide mononucleotide — rather than NAD+ itself, on the rationale that the intact molecule is poorly absorbed orally. Whether precursors meaningfully raise tissue NAD+ in humans, and by how much, is precisely the question the current research is working on.
Route selection is a clinical decision, and for many patients an IV route within an existing wellness program is more appropriate than a prescribed injectable protocol.
Delivery routes are not interchangeable
Intravenous / injectable
NAD+ itself
- Delivered directly to the bloodstream, bypassing digestion
- Infusions run slowly — rapid administration causes chest tightness and nausea
- Subcutaneous injection allows smaller, more frequent dosing
- Administered within a clinical setting or a prescribed protocol
Oral precursors
NR and NMN, not NAD+
- The intact NAD+ molecule is poorly absorbed orally
- Supplements typically supply precursor molecules instead
- How much they raise tissue NAD+ in humans is an open research question
- Widely available without a prescription
Related reading
About compounded medications
Compounded medications do not undergo pre-market review or an FDA-approval process. They may differ from commercially available or FDA-approved drugs in efficacy, safety, risk, and side-effect profiles. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications.
Curious whether this fits your goals?
Joining a program includes the full intake: a secure health-history form and a brief telehealth physician evaluation, with medical clearance before anything ships — and your first month is fully refunded if the physician determines therapy isn’t appropriate. Not everyone qualifies, and we will tell you if you do not.
Start Your ProgramFrequently asked questions
Is NAD+ a peptide?
What does NAD+ do in the body?
Why do NAD+ levels decline with age?
What is the difference between IV NAD+ and oral NAD+ supplements?
Clinical references
Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:
- Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021. pmc.ncbi.nlm.nih.gov
- Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism. 2018. pmc.ncbi.nlm.nih.gov
- U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov
Ready to talk to a physician?
Start your program enrollment — the comprehensive intake, physician Good Faith Examination, and medical clearance. A physician reviews your goals and labs and tells you honestly whether therapy is appropriate. Your fee credits in full toward your first month of membership. Available nationwide.
Start Your ProgramServing Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.
This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.